OMER vs PGEN Stock Comparison
OMER currently leads PGEN in this stock comparison, with AIQ scores of 64 vs 55. The clearest difference is momentum, while PGEN has the stronger quality profile.
What is the main difference between OMER and PGEN?
OMER leads the current stock comparison as Omeros Corporation, with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Omeros Corporation vs Precigen, Inc.
OMER leads
OMER leads by 9 AIQ points, primarily on Momentum and Value, and the lead has widened from 5 points over 30 sessions. Wall Street currently favors PGEN on target upside.
Fragile: 3 of 6 evidence groups support OMER, its lead is widening, and its current signal state is conflicted.
Omeros Corporation
Precigen, Inc.
The Algovestiq AIQ Score currently favors OMER over PGEN, 64 versus 55 as of Nov 15, 2026. OMER's advantage is driven primarily by stronger momentum and value, while PGEN holds the stronger quality profile. OMER also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors PGEN. 3 of 6 covered evidence groups favor OMER today, and the comparison is rated Fragile on stability: only 3 of 6 covered evidence groups agree. OMER lead: Strengthening — the AIQ differential moved from 5 to 9 points over 30 sessions.
Compare Omeros Corporation and Precigen, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare OMER and PGEN against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum79 vs 55OMER +24
- Value73 vs 63OMER +10
- Quality55 vs 60PGEN +5
- Risk Resilience33 vs 31Even
3 of 6 evidence groups favor OMER. OMER’s edge is concentrated in momentum and value; PGEN keeps a meaningful quality edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Momentum -1, not enough on its own to move the overall score.
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.76x)
- RSI Midline Rejection — bearish, momentum, short horizon
No factor moved materially.
New signals
- ADX Trend Strengthening — neutral, trend, medium horizon
- Keltner Channel Breakdown — bearish, volatility, short horizon
OMER's lead narrowed by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — OMER and PGEN both carry a full feed there.
The central trade-off
OMER (Omeros Corporation): the stronger current systematic profile, led by momentum and value.
PGEN (Precigen, Inc.): the counter-case, on quality, fundamentals, analyst expectations — but at materially higher volatility, 127% against 54.9%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
OMEROMER on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
OMEROMER on combined revenue and EPS growth.
Value
OMEROMER on the peer-relative Value factor, by 10 points.
Momentum
OMEROMER on the Momentum factor, by 24 points.
Lower downside
OMEROMER carries the lower 1-month annualized volatility.
Analyst upside
PGENPGEN on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors OMER, analyst targets favor PGEN. That disagreement is the most useful thing on this page.
| Measure | OMER | PGEN | Note |
|---|---|---|---|
| Implied upside to target | +25.8% | +164.3% | PGEN has more room |
| Target dispersion | 0% | 0% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 3 | 4 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor OMER. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | OMER | 64 vs 55 |
| Fundamentals | PGENon balance | revenue growth 188.4% vs 34.9%; EPS growth -76.9% vs 66.7%; TTM ROE -25.8% vs 42.7%; gross margin 95.8% vs 91%; operating margin -189.5% vs 21.4% — PGEN takes 3 of 5 decided legs, not all of them |
| Valuation | OMER | Value 73 vs 63 |
| Technicals | OMER | Price vs 50-day -4.3% vs -32.6%; vs 200-day 27% vs -14% |
| Risk Resilience | Even | Risk Resilience 33 vs 31 |
| Analyst expectations | PGEN | Target upside 25.8% vs 164.3% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of OMER and PGEN and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is moderate at 9 points.
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been widening. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on OMER.
How the comparison changed
120 daily snapshots · May 27 – Nov 13OMER lead: Strengthening — the AIQ differential moved from 5 to 9 points over 30 sessions.
- Today
- OMER +9
- 64 vs 55
- 7 sessions ago
- OMER +3
- 65 vs 62
- 30 sessions ago
- OMER +5
- 66 vs 61
- 90 sessions ago
- Level
- 58 vs 58
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 3 bearish / 2 neutral, conflicted
Only OMER
- ADX Trend Weakening — neutral, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.76x)
- RSI Midline Rejection — bearish, momentum, short horizon
1 bullish / 2 bearish / 2 neutral, conflicted
Only PGEN
- ADX Trend Strengthening — neutral, trend, medium horizon
- Keltner Channel Breakdown — bearish, volatility, short horizon
Both carry 3 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode, Beta Spike Warning.
OMER leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -2.78%, AIQ 0 points).
Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -2.58%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1PGEN closes the Momentum gap — currently 24 points behind, the largest single contributor to OMER's edge.
- 2PGEN's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
- 3OMER's conflicting signal state resolves bearish — it currently carries 1 bullish and 3 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
PGEN leads on balance| Metric | OMER | PGEN |
|---|---|---|
| Revenue growth (YoY) | 188.4% | 34.9% |
| EPS growth (YoY) | -76.9% | 66.7% |
| Gross margin | 95.8% | 91% |
| Operating margin | -189.5% | 21.4% |
| Return on equity (TTM) | -25.8% | 42.7% |
| Debt to equity | -1.63 | 1.18 |
Performance
OMER leads 5 of 6 windows| Metric | OMER | PGEN |
|---|---|---|
| 1 week (5 sessions) | 3.4% | 1.6% |
| 1 month (20 sessions) | 8% | -28.9% |
| 3 months (63 sessions) | 0.7% | -30.7% |
| 6 months (126 sessions) | 42.8% | 2.7% |
| Year to date | 1.8% | 8.6% |
| 1 year (252 sessions) | 153.8% | 12.9% |
Technicals
OMER has the stronger structure| Metric | OMER | PGEN |
|---|---|---|
| RSI (14) | 47.9 | 34.2 |
| ADX (14) | 12.2 | 28.8 |
| Price vs 50-day | -4.3% | -32.6% |
| Price vs 200-day | 27% | -14% |
| Volatility (1M, annualized) | 54.9% | 127% |
Risk
Split| Metric | OMER | PGEN |
|---|---|---|
| Beta | 1.6 | 1.62 |
| Sharpe ratio | 1.36 | 0.57 |
| Sortino ratio | 3.04 | 0.87 |
| Max drawdown | -49.5% | -50.7% |
| Current drawdown | -16.9% | -47% |
| Annualized volatility | 110.8% | 85.4% |
| Value at risk (95%) | -6.7% | -7.2% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, OMER or PGEN?
On the Algovestiq AIQ Score, OMER is the stronger of the two as of Nov 15, 2026, scoring 64 against PGEN's 55. The edge comes from momentum and value. PGEN is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is OMER or PGEN the better buy right now?
OMER carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 3 of 6 covered evidence groups agree. Treat the lead as provisional.
Why does the AIQ Score favor OMER over PGEN?
The composite weights Quality, Value, Momentum and Risk Resilience. OMER leads Momentum by 24 points; OMER leads Value by 10 points; PGEN leads Quality by 5 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, OMER or PGEN?
Analyst price targets imply +25.8% upside for OMER and +164.3% for PGEN, so the Street currently favors PGEN. That points the opposite way to the AIQ Score, which favors OMER. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, OMER or PGEN?
OMER is the better-valued of the two on the peer-relative Value factor. OMER on the peer-relative Value factor, by 10 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, OMER or PGEN?
OMER on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, OMER or PGEN?
OMER on the Momentum factor, by 24 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, OMER or PGEN?
OMER is the more resilient of the two, so the other name carries the higher downside risk. OMER carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is OMER more profitable than PGEN?
The profitability evidence is mixed: gross margin 95.8% vs 91%; operating margin -189.5% vs 21.4%; ttm roe -25.8% vs 42.7%. OMER leads on one measure and PGEN on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is OMER's lead over PGEN getting stronger or weaker?
OMER lead: Strengthening — the AIQ differential moved from 5 to 9 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the OMER vs PGEN verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: PGEN closes the Momentum gap — currently 24 points behind, the largest single contributor to OMER's edge; PGEN's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; OMER's conflicting signal state resolves bearish — it currently carries 1 bullish and 3 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about OMER and PGEN?
OMER: 1 bullish / 3 bearish / 2 neutral, conflicted. PGEN: 1 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on OMER is Golden Cross Active (bullish, long horizon). On PGEN it is Golden Cross Active (bullish, long horizon).
Compare OMER and PGEN with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.